Pharmacological agents that inhibit NO production, including inducible nitric oxide synthase (iNOS) inhibitors, have the potential to treat cSCC and its precancerous lesions, such as actinic keratosis, by augmenting anti-tumor immune responses (79). The gene discussed is NOS2; the disease is neoplasm.